Do vasodilating beta-blockers improve glucose and lipid metabolism and reduce coronary artery disease risk in high-risk patients with hypertension?
Vasodilating beta-blockers may offer metabolic benefits that could reduce coronary artery disease risk in high-risk hypertensive patients.
Improvements in glucose and lipid metabolism mediated by vasodilating beta-blockers may help reduce coronary artery disease risk among high-risk patients with hypertension.
Vivian Fonseca (Wed,) studied this question.